Prognostic Value of EGFR Mutation and ERCC1 in Patients with Non-Small Cell Lung Cancer Undergoing Platinum-Based Chemotherapy
作者： Fumie Yamashita , Koichi Azuma , Tsukasa Yoshida , Kazuhiko Yamada , Akihiko Kawahara
DOI: 10.1371/JOURNAL.PONE.0071356
关键词:
摘要: Background In order to improve the outcome of patients with non-small cell lung cancer (NSCLC), a biomarker that can predict efficacy chemotherapy is needed. The aim this study was assess role EGFR mutations and ERCC1 in predicting platinum-based NSCLC.
harvard.edu
doaj.org参考文章(25)
D.M Parkin, F.I Bray, S.S Devesa, Cancer burden in the year 2000. The global picture. European Journal of Cancer. ,vol. 37, pp. 4- 66 ,(2001) , 10.1016/S0959-8049(01)00267-2
Koichi Azuma, Tetsuro Sasada, Akihiko Kawahara, Sinzo Takamori, Satoshi Hattori, Jiro Ikeda, Kyogo Itoh, Akira Yamada, Masayoshi Kage, Michihiko Kuwano, Hisamichi Aizawa, Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel Lung Cancer. ,vol. 64, pp. 326- 333 ,(2009) , 10.1016/J.LUNGCAN.2008.09.002
George R Simon, Swati Sharma, Alan Cantor, Prudence Smith, Gerold Bepler, ERCC1 Expression Is a Predictor of Survival in Resected Patients With Non-small Cell Lung Cancer Chest. ,vol. 127, pp. 978- 983 ,(2005) , 10.1378/CHEST.127.3.978
Meina Wu, Jun Zhao, Sonya Wei Song, Minglei Zhuo, Xin Wang, Hua Bai, Shuhang Wang, Lu Yang, Tongtong An, Yan Zhang, Jianchun Duan, Yuyan Wang, Qingzhi Guo, Xuyi Liu, Ninghong Liu, Jie Wang, EGFR mutations are associated with prognosis but not with the response to front-line chemotherapy in the Chinese patients with advanced non-small cell lung cancer Lung Cancer. ,vol. 67, pp. 343- 347 ,(2010) , 10.1016/J.LUNGCAN.2009.04.011
Katsuyuki Hotta, Katsuyuki Kiura, Shinichi Toyooka, Nagio Takigawa, Junichi Soh, Yoshiro Fujiwara, Masahiro Tabata, Hiroshi Date, Mitsune Tanimoto, Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer. Journal of Thoracic Oncology. ,vol. 2, pp. 632- 637 ,(2007) , 10.1097/JTO.0B013E318074BC0D
Jin Hyun Park, Se-Hoon Lee, Bhumsuk Keam, Tae Min Kim, Dong-Wan Kim, Seok-Chul Yang, Young Whan Kim, Dae Seog Heo, None, EGFR mutations as a predictive marker of cytotoxic chemotherapy Lung Cancer. ,vol. 77, pp. 433- 437 ,(2012) , 10.1016/J.LUNGCAN.2012.03.020
Akihiko Kawahara, Koichi Azuma, Satoshi Hattori, Kazutaka Nakashima, Yuji Basaki, Jun Akiba, Sinzo Takamori, Hisamichi Aizawa, Takashi Yanagawa, Hiroto Izumi, Kimitoshi Kohno, Suminori Kono, Masayoshi Kage, Michihiko Kuwano, Mayumi Ono, The close correlation between 8-hydroxy-2′-deoxyguanosine and epidermal growth factor receptor activating mutation in non–small cell lung cancer☆ Human Pathology. ,vol. 41, pp. 951- 959 ,(2010) , 10.1016/J.HUMPATH.2009.12.007
David R. Gandara, Peter Grimminger, Philip C. Mack, Primo N. Lara, Tianhong Li, Peter V. Danenberg, Kathleen D. Danenberg, Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer Journal of Thoracic Oncology. ,vol. 5, pp. 1933- 1938 ,(2010) , 10.1097/JTO.0B013E3181FD418D
Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, Sara M. Haserlat, Jeffrey G. Supko, Frank G. Haluska, David N. Louis, David C. Christiani, Jeff Settleman, Daniel A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib The New England Journal of Medicine. ,vol. 350, pp. 2129- 2139 ,(2004) , 10.1056/NEJMOA040938
Richard A. Hubner, Richard D. Riley, Lucinda J. Billingham, Sanjay Popat, Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0025164